Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
stocknews5h
3 Biotech Innovators Advancing Genetic Therapies
The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...
The Pharma Letter6h
Vertex has CF cornered, but won’t stop till every patient feels the same
Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space. How has ...
Bernstein Remains a Hold on Vertex Pharmaceuticals (VRTX)
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by CWA Asset Management Group LLC
CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...
Nordea Investment Management AB Purchases 55,739 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...
MM&M19h
Obesity meds to lead charge as pharma sales ride ‘momentum’ into 2025
While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...